Cytosorbents (CTSO) Net Income Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 108.74 Bn | 99.52 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 68.40 Bn | 66.95 Bn | 3.61 Bn | 62.29% |
| 5 | Edwards Lifesciences | 47.42 Bn | 43.74 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.47 Bn | 26.18 Bn | 1.98 Bn | 2.38% |
| 7 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | 60.12% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.39 Bn | 2.07 Bn | 280.49% |
| 10 | Cytosorbents | 22.59 Mn | 17.79 Mn | 6.13 Mn | -14.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.67% |
| Dec 31, 2025 | -74.80% |
| Sep 30, 2025 | 36.18% |
| Jun 30, 2025 | -32.34% |
| Mar 31, 2025 | 45.17% |
| Dec 31, 2024 | 34.75% |
| Sep 30, 2024 | 24.40% |
| Jun 30, 2024 | 2.80% |
| Mar 31, 2024 | -13.47% |
| Dec 31, 2023 | -108.41% |
| Sep 30, 2023 | -122.01% |
| Jun 30, 2023 | -32.05% |
| Mar 31, 2023 | -28.48% |
| Dec 31, 2022 | 42.11% |
| Sep 30, 2022 | -21.01% |
| Jun 30, 2022 | -45.29% |
| Mar 31, 2022 | -22.45% |
| Dec 31, 2021 | -19.87% |
| Sep 30, 2021 | -28.71% |
| Jun 30, 2021 | 7.03% |